DDInter899 DDInter612
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved
Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed that this agent is a potent inhibitor of both forms. Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018.
Duvelisib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Duvelisib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Duvelisib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabazitaxel
Duvelisib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Duvelisib {u} may lead to a major life threatening interaction when taken with {v} Sonidegib
Duvelisib {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Duvelisib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Duvelisib may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Duvelisib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Duvelisib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Duvelisib may lead to a major life threatening interaction when taken with Sonidegib
Duvelisib may lead to a major life threatening interaction when taken with Upadacitinib